EPI-2021-0210 SUP FIG 3

(A) Bubble charts demonstrating significant correlations between TRIM58 expression and methylation in pan-cancer samples. The correlation coefficient was determined by Pearson’s correlation. (B) Differences in TRIM58 expression in normal and tumor pan-cancer samples. (* represents for p < 0.05, ** represent for p < 0.01, *** represent for p < 0.001) (HNSC: Head and Neck squamous cell carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; PRAD: Prostate adenocarcinoma; LUSC: Lung squamous cell carcinoma; COAD: Colon adenocarcinoma; PAAD: Pancreatic adenocarcinoma; LUAD: Lung adenocarcinoma; ESCA: Esophageal carcinoma; SKCM: Skin Cutaneous Melanoma; UCEC: Uterine Corpus Endometrial Carcinoma; CHOL: Cholangiocarcinoma; BLCA: Bladder Urothelial Carcinoma; KIRC: Kidney renal clear cell carcinoma; LIHC: Liver hepatocellular carcinoma; THCA: Thyroid carcinoma; ACC: Adrenocortical carcinoma; GBM: Glioblastoma multiforme; STAD: Stomach adenocarcinoma; READ: Rectum adenocarcinoma). (C) Immunohistochemical staining for TRIM58 in breast cancer samples and other cancer types form the HPA database. (D) Forest plots derived from univariate Cox regression analyses highlighting TRIM58 methylation levels associated with OS in pan-cancer samples. Hazard ratios and 95% confidence intervals are shown (* represents for p < 0.05, ** represent for p < 0.01).